U.S. markets closed

Jasper Therapeutics, Inc. (JSPR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.8100-0.0700 (-3.72%)
At close: 04:00PM EDT
1.8100 0.00 (0.00%)
After hours: 07:49PM EDT

Jasper Therapeutics, Inc.

2200 Bridge Pkwy
Suite 102
Redwood City, CA 94065
United States
650 549 1400

Full Time Employees35

Key Executives

NameTitlePayExercisedYear Born
Dr. Judith Anne Shizuru M.D., Ph.D.Co-Founder, Chair of Scientific Advisory Board & Director260.77kN/A1957
Mr. Jeetinder Singh Mahal M.B.A.CFO, COO & Corp. Sec.461.12kN/A1973
Dr. Kevin N. Heller M.D.Exec. VP of R&D617.99kN/A1972
Mr. Ronald A. MartellPres, CEO & DirectorN/AN/A1962
Dr. Susan Prohaska Ph.D.Co-Founder and VP of Operations & Program ManagementN/AN/AN/A
Dr. Carol ZoltowskiSr. VP of Regulatory Affairs & QualityN/AN/A1950
Dr. Wendy Pang M.D., Ph.D.Sr. VP of Research & Translational MedicineN/AN/AN/A
Dr. Daniel C. Adelman M.D.Acting Chief Medical OfficerN/AN/A1957
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

Corporate Governance

Jasper Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.